Press Releases
Oxford Medical Diagnostics and V&F join forces in the field of mass spectrometry
Oxford Medical Diagnostics (OMD), the UK developer of breath based, medical diagnostic technology for the rapid, non-invasive, accurate and low-cost diagnosis and monitoring of metabolic and infectious diseases; and V&F Analyse- und Messtechnik GmbH (V&F), a provider of analytical...
Press Releases
Nycomed’s novel COPD therapy roflumilast receives FDA approval
Nycomed’s US partner Forest Laboratories, Inc.announced that DalirespTM (roflumilast) was approved by the US Food and Drug Administration (FDA) as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated...
Press Releases
PharmaDiagnostics appoints director of assay development
PharmaDiagnostics NV, a company developing and marketing a broadly-enabling, label-free screening technology that uniquely does not require specialized instrumentation, announces today the appointment of Dr Sylviane Boucharens as director of assay development. Sylviane joins from Merck’s MSD site in...
Press Releases
Patent plethora in 2010 breaks record for Biocitech technology park residents
Biocitech SAS, the Paris life science technology park, today announced that its 25 resident companies applied for a bumper number of patents with a nearly 70 per cent leap to 147 in 2010. This represents an almost five-fold increase...
Press Releases
Apricus Biosciences Announced European Patient Coverage For Mycova For Nail Fungus
Apricus Biosciences, Inc. announced that the European Patent Office will grant a patent for the company's MycoVa™ product for treating onychomycosis (commonly referred to as nail fungus). The European Patent Office recently issued a "notice of allowance" for the...
Press Releases
Trophos successfully completes phase 1 study for novel cardioprotective compound, TRO40303
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the successful completion of its phase 1 dose escalation study of TRO40303, a...
Press Releases
Novartis gains positive CHMP opinion for Rasilamlo(TM), a single-pill combination of aliskiren and amlodipine to treat high blood pressure
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Rasilamlo(TM) (aliskiren and amlodipine) to treat high blood pressure patients not adequately controlled by either aliskiren or amlodipine alone. Rasilamlo combines in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read